Related Experiment Video
Updated: Feb 10, 2026
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
E2F1 inhibition mediates cell death of metastatic melanoma
Florian Rouaud1,2, Nedra Hamouda-Tekaya1,2, Michaël Cerezo1,2
1INSERM, U1065, team 12, Study of molecular mechanisms involved in pigmentation and melanoma using translational approaches, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Abstract:
Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeutical approaches to bypass resistance and achieve more prolonged responses. In this context, we were interested in E2F1, a transcription factor that plays a major role in the control of cell cycle under physiological and pathological conditions. Here we confirmed that E2F1 is highly expressed in melanoma cells. Inhibition of E2F1 activity further increased melanoma cell death and senescence, both in vitro and in vivo. Moreover, blocking E2F1 also induced death of melanoma cells resistant to BRAF inhibitors. In conclusion, our studies suggest that targeting the E2F1 signaling pathway may be therapeutically relevant for melanoma.
Insights
Targeting the E2F1 transcription factor shows promise for melanoma treatment. Inhibiting E2F1 promotes melanoma cell death and senescence, even in drug-resistant cases, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Metastatic melanoma remains a lethal cancer despite current targeted therapies and immunotherapies.
- Resistance to BRAF inhibitors and other treatments necessitates novel therapeutic strategies.
- The transcription factor E2F1 is crucial for cell cycle regulation and implicated in cancer progression.
Purpose of the Study:
- To investigate the role of E2F1 in melanoma.
- To evaluate the therapeutic potential of inhibiting E2F1 in melanoma, including drug-resistant models.
Main Methods:
- Confirmation of E2F1 expression in melanoma cells.
- Inhibition of E2F1 activity in vitro and in vivo.
- Assessment of melanoma cell death and senescence.
- Evaluation of E2F1 inhibition in BRAF inhibitor-resistant melanoma cells.
Main Results:
- E2F1 is highly expressed in melanoma cells.
- Inhibition of E2F1 significantly increased melanoma cell death and senescence.
- E2F1 blockade effectively induced death in melanoma cells resistant to BRAF inhibitors.
- Both in vitro and in vivo studies demonstrated the efficacy of E2F1 inhibition.
Conclusions:
- Targeting the E2F1 signaling pathway represents a potentially effective therapeutic strategy for melanoma.
- E2F1 inhibition offers a promising approach to overcome resistance to existing melanoma treatments.
- Further research into E2F1-targeted therapies could lead to improved patient outcomes in melanoma.
Related Concept Videos
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
00:46Feedback Inhibition
01:30Enzyme Inhibition
01:39Receptor-mediated Endocytosis
01:40Cell-mediated Immune Responses